Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
- 22 July 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Hormones and Cancer
- Vol. 5 (5), 265-273
- https://doi.org/10.1007/s12672-014-0190-1
Abstract
The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment. Both drugs were designed to further suppress androgen receptor (AR) signaling, which is restored following first-line androgen deprivation therapies. Resistance to enzalutamide and abiraterone, however, is again marked by a return of AR signaling, indicating a remarkable “addiction” of prostate cancer cells to the AR pathway. Several mechanisms of castration resistance have been uncovered in the past decades, featuring a wide spectrum of molecular alterations that may explain sustained AR signaling in castration-resistant prostate cancers (CRPC). Among these, the androgen receptor splice variants (AR-Vs), particularly variant 7 (AR-V7), have been implicated in resistance to enzalutamide and abiraterone in preclinical studies, and they cannot be targeted by currently available AR-directed drugs. Drug development for AR-V-associated CRPC may therefore be necessary to augment the preexisting treatment repertoire. In this mini-review, we will discuss general mechanisms of resistance to AR-directed therapies, with a focus on the role of androgen receptor splice variants in the new era of treating advanced prostate cancer with enzalutamide and abiraterone.Keywords
This publication has 102 references indexed in Scilit:
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signalingCell Death & Disease, 2013
- Overcoming mutation-based resistance to antiandrogens with rational drug designeLife, 2013
- Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cellsThe International Journal of Biochemistry & Cell Biology, 2013
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1Cancer Cell, 2011
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activitiesThe Prostate, 2011
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerNature Medicine, 2009
- Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology, 2008
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003